Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033443 | PMC |
http://dx.doi.org/10.1093/jlb/lsw006 | DOI Listing |
J Law Biosci
April 2016
School of Public Health, University of Alberta, Canada.
J Law Biosci
November 2015
College of Law, Depaul University, Chicago, IL 60604, USA.
This comment on by Tania Bubela, Saurabh Vishnubhakat, and Robert Cook-Deegan discusses the authors' description of how patents relating to the gene coding for a protein involved in Alzheimer's disease were obtained and used to sue scientific researchers, of how conflicts can arise among groups of researchers, and of how important research can be delayed or foregone by the exercise of patent rights. The authors sought to counter with evidence the optimistic views that patents on such research tools are not used to sue researchers and thus do not impede sequential innovation. The authors proposed legal reforms to avoid such impediments, particularly adoption of a broader experimental use limit to the patent infringement right.
View Article and Find Full Text PDFJ Law Biosci
November 2015
Department of Molecular Neuroscience, UCL Institute of Neurology, Queens Square, London WC1N 3BG, UK.
J Law Biosci
November 2015
Harry and Lillian Hastings Professor of Law and Director of the Institute for Innovation Law, University of California Hastings College of the Law.
Research universities have made enormous contributions to the field of medicine and the treatment of human disease. Alone or in collaboration with pharmaceutical companies, academic researchers have added to the store of knowledge that has led to numerous life science breakthroughs. A new chapter may be opening for academic researchers, however, that could lead to a darker tale.
View Article and Find Full Text PDFZhongguo Ying Yong Sheng Li Xue Za Zhi
April 2016
Department of Biology, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325035, China.
Objective: To investigate the effects of pirfenidone on CCl4-induced liver fibrosis in mice.
Methods: After 8-week feeding, 40 healthy male SPF ICR mice were randomly divided into 4 groups:liver fibrosis group (CCL group), low doses of Pirfenidone group (PFD-L group), high doses of Pirfenidone group (PFD-H group) and control group. The mice in CCL group, low doses of Pirfenidone group (PFD-L group), high doses of Pirfenidone group (PFD-H group) were injected intraperitoneally with 0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!